Health Trials

Lymphoma, Non-Hodgkin's, Adult

3

Review clinical trials related to Lymphoma, Non-Hodgkin's, Adult. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)

Participants needed: 35
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Beth Israel Deaconess Medical CenterUpdated: Mar 13, 2026Locations: 3
Eligibility criteria

Biopsy-confirmed (fresh or archival tissue) follicular lymphoma grade 1-3A that... [+25]

Use of investigational agents incorporated into prior induction therapy [+13]

Read more
Status: Recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.

Participants needed: 21
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Estrella Biopharma, Inc.Updated: Aug 7, 2025Locations: 2
Eligibility criteria

Age 18 years or older at the time of informed consent [+11]

Prior CD19-targeted cellular therapy [+13]

Read more
Status: Not yet recruiting

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

The purpose of this research is to help researchers find out if SP-3164 is safe and if it may be of benefit in the treatment of patients with Non-Hodgkin's lymphoma that has progressed after prior treatment, or that never responded to previous treatment.

Participants needed: 72
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Salarius Pharmaceuticals, LLCUpdated: Nov 22, 2023
Eligibility criteria

require treatment in the opinion of the Investigator [+1]

Read more